CD25 preselective anti-HIV vectors for improved HIV gene therapy

Human Gene Therapy Methods

Volumn 23, Issue 6, 2012, Pages 366-375

  Kalomoiris, Stefanos ^a   Lawson, Je'Tai ^a   Chen, Rachel X ^a   Bauer, Gerhard ^a   Nolta, Jan A ^a   Anderson, Joseph S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; LENTIVIRUS VECTOR;

ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PURIFICATION; SAFETY; STEM CELL GENE THERAPY; VIRAL GENE THERAPY;

ANTIGENS, CD34; GENETIC THERAPY; GENETIC VECTORS; HEK293 CELLS; HEMATOPOIETIC STEM CELLS; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LENTIVIRUS; TRANSDUCTION, GENETIC;

EID: 84878746121     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2012.142     Document Type: Article

References (30)

1. Anderson, J.S., Javien, J., Nolta, J.A., et al. (2009). Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5alpha protein, a CCR5 shRNA, and a TAR decoy. Mol. Ther. 17, 2103-2114.
2. Baldanti, F., Paolucci, S., Gulminetti, R., et al. (2010). Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens. J. Med. Virol. 82, 116-122.
3. Barouch, D.H. (2008). Challenges in the development of an HIV-1 vaccine. Nature 455, 613-619.
4. Bauer, G., Valdez, P., Kearns, K., et al. (1997). Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factormobilized CD34 + cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood 89, 2259-2267. (Pubitemid 27143270)
5. Clark, F.J., Gregg, R., Piper, K., et al. (2004). Chronic graft-versushost-disease is associated with increased numbers of peripheral blood CD4 +CD25high regulatory T cells. Blood. 103: 2410-2416. (Pubitemid 38326268)
6. DiGiusto, D., Krishnan, A., Li, L., et al. (2010). RNA-based gene therapy for HIV with lentiviral vector-modified CD34( + ) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci. Transl. Med. 36, 36ra43.
7. Domingo, P., Estrada, V., Lopez-Aldeguer, J., et al. (2012). Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy. AIDS Rev. 14, 112-123.
8. Edgeworth, R.L., San, J.H., Rosenweig, J.A., et al. (2002). Vaccine development against HIV-1: current perspectives and future directions. Immunol. Res. 25, 53-74. (Pubitemid 34155249)
9. Gazzola, L., Tincati, C., Bellistri, G.M., et al. (2009). The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin. Infect. Dis. 48, 328-337.
10. Graham SM, Jalalian-Lechak Z, Shafi J, et al. (2012). Antiretroviral treatment interruptions predict female genital shedding of genotypically resistant HIV-1 RNA. J. Acquir. Immune. Defic. Syndr. 60, 511-518.
11. Grant, A.J., Roessler, E., Ju, G., et al. (1992). The interleukin 2 receptor (IL-2R) the IL-2R alpha subunit alters the function of the IL-2R beta subunit to enhance IL-2 binding and signaling by mechanisms that do not require binding of IL-2 to IL-2R alpha subunit. Proc. Natl. Acad. Sci. USA 89, 2165-2169.
12. Hutter, G., Nowak, D., Mossner, M., et al. (2009). Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360, 692-698.
13. Johnson, V.A., Brun-Vezinet, F., Clotet, B., et al. (2010). Update of the drug resistance mutations in HIV-1: December 2010. Top. HIV Med. 18, 156-63.
14. Kalmar E.M., Sanabani S.S., Charlys da Costa A., et al. (2012). Evaluation of HIV-1 resistance to antiretroviral drugs among 150 patients after six months of therapeutic interruption. Int. J. STD. AIDS 23, 120-125.
15. Kohn, D.B., Bauer, G., Rice, C.R., et al. (1999). A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34( + ) cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 94, 368-371. (Pubitemid 29300172)
16. Kuritzkes, D.R. (2011). Drug Resistance in HIV-1. Curr. Opin. Virol. 1, 582-589.
17. Kuziel, W.A., and Greene, W.C. (1990). Interleukin-2 and IL-2 receptor: new insights intostructure and function. J. Invest. Dermatol. 94, 27S-32S. (Pubitemid 20213064)
18. Lewden, C., Chene, G., Morlat, P., et al. (2007). HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J. Acquir. Immune. Defic. Syndr. 46, 72-77. (Pubitemid 47514615)
19. Macias, J., Neukam, K., Mallolas, J., et al. (2012). Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavirboosted protease inhibitor in HIV/HCV-coinfected patients. HIV Clin. Trials 13, 61-69.
20. Mehandru, S., Poles, M.A., Tenner-Racz, K., et al. (2006). Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med. 3, e484.
21. Minami, Y., Kono, T., Miyazaki, T., et al. (1993). The IL-2 receptor complex: Its structure, function, and target genes. Annu. Rev. Immunol. 11, 245-267. (Pubitemid 23115008)
22. Mitsuyasu, R.T., Merigan, T.C., Carr, A., et al. (2009). Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34 + cells. Nat. Med. 15, 285-292.
23. Podsakoff, G.M., Engel, B.C., Carbonaro, D.A., et al. (2005). Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34( + ) cells. Mol. Ther. 12, 77-86. (Pubitemid 40862359)
24. Shimizu, S., Hong, P., Arumugam, B., et al. (2010). A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood 115, 1534-1544.
25. Strayer, D.S., Akkina, R., Bunnel, B.A., et al. (2005). Current Status of Gene Therapy Strategies to Treat HIV/AIDS. Mol. Ther. 11, 823-841.
26. ter Brake, O., Legrand, N., von Eije, K.J., et al. (2009). Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system (Rag-2(-/-)gammac(-/-)) mouse model. Gene Ther. 16, 148-153.
27. Tilton, J.C., Wilen, C.B., Didigu, C.A., et al. (2010). A maraviroc resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J. Virol. 84, 10863-10876.
28. Trobridge, G.D., Wu, R.A., Beard, B.C., et al. (2009). Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection. PloS One 4, e7693.
29. Walker, J.E., Chen, R.X., McGee, J., et al. (2012). Generation of an HIV-1-resistant immune system with CD34( + ) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector. J. Virol. 86: 5719-5729.
30. Zorn, E., Kim, H.T., Lee, S.J., et al. (2005). Reduced frequency of FOXP3 + CD4+ CD25 + regulatory T cells in patients with chronic graft-versus-host disease. Blood. 106: 2903-2911. (Pubitemid 41510772)